The inclusion of CDK1 in tumor marker testing is of great significance, as well as the development of new anti-CDK1 drugs targeting CDK1, anti-CDK1 combined with immunotherapy or combined with chemotherapy, making it possible to extend the median survival time of tumor patients. The gene discussed is CDK1; the disease is neoplasm.